Papers
3
Total Citations
880
H-Index
3
About
Dr. Kerri Kendrick is a leading urologic oncologist whose landmark research has reshaped the surgical management of bladder cancer. She is best known as the principal investigator of the landmark RAZOR trial, a phase 3, non-inferiority study that rigorously compared robot-assisted radical cystectomy (RARC) to open radical cystectomy (ORC). Her seminal 2018 paper in *The Lancet* (760 citations) established that robotic surgery is non-inferior to open surgery for 2-year progression-free survival, providing high-level evidence for the adoption of minimally invasive techniques. Dr. Kendrick’s subsequent work has further defined the field, including a 3-year follow-up analysis (115 citations) confirming durable oncologic outcomes and a 2025 study on complication and readmission rates. Her contributions have directly informed clinical guidelines and empowered surgeons and patients with data-driven choices. Through the RAZOR trial, Dr. Kendrick has not only validated robotic cystectomy but also set a new standard for evidence-based surgical innovation in urologic oncology.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3